Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGER: Surgery and Aflibercept for Submacular Haemorrhage in Wet AMD
NCT04663750Phase 3Recruiting
- Sponsor
- King's College Hospital
- Start
- Apr 2021
- Primary completion
- Dec 2028
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 7
01
Overview
A Phase 3 trial of tissue-plasminogen activator in submacular hemorrhage (SMH), exudative macular degeneration, sponsored by King's College Hospital. Started Apr 2021; status: recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
submacular hemorrhage (SMH)exudative macular degeneration
Beyond the preview
Go deeper on NCT04663750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04663750.